DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced that it has entered into an agreement with a larger regional health plan. The agreement calls for DRIO to provide its digital therapeutic solution for diabetes to eligible Medicaid members in and around the mid-Atlantic region. According to the announcement, the contract should contribute to DarioHealth revenue sometime in Q2 2022. DRIO noted that Medicaid participants dealing with diabetes pay approximately three times higher cost of care compared to those living without the disease, resulting in significant challenges in serving this population. The new agreement aims to engage members through Dario’s personalized digital therapeutics to deliver innovative solutions and improve access to digital care that has been shown to improve health and lower costs. “We are pleased to partner with a leading regional plan to deliver cutting-edge diabetes care to their Medicaid members, an essential component often missing from public health programs,” said DarioHealth president and general manager of North American Rick Anderson in the press release. “We have proven that we can engage people across socioeconomic backgrounds and believe that there are significant opportunities to address health inequities, through innovation, in Medicaid populations with our solution.”
To view the full press release, visit https://ibn.fm/o7iAy
About DarioHealth Corp.
DarioHealth Corp. is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market, covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. Dario’s next-generation, AI-powered, digital therapeutic platform supports more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions; intuitive, clinically proven digital tools; high-quality software; and coaching to help individuals improve health and sustain meaningful outcomes. Dario’s unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results. Dario’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology and utilizes a performance-based approach to improve its users’ health. On the path to better health, Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
